Press Releases
Search
-
04 May 2022
Business & Solutions
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® Joint Infection (JI) Panel has received De Novo authorization from the US Food and Drug Administration (FDA). This panel tests for 31 pathogens implicated in most acute joint infections, and also includes 8 antimicrobial resistance (AMR) genes.
-
12 Apr 2022
Antimicrobial Resistance
Specific Diagnostics acquisition
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures.
-
11 Apr 2022
Financial Information
First-Quarter 2022 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2022.
-
18 Mar 2022
Business & Solutions
bioMérieux receives FDA 510(k) clearance for its VITEK® MS PRIME new MALDI-TOF mass spectrometry identification system
bioMérieux, a world leader in the field of in vitro diagnostics, announces that VITEK® MS PRIME, its new MALDI-TOF mass spectrometry identification system, has received 510(k) clearance from the U.S. ...
-
02 Mar 2022
Financial Information
bioMérieux – 2021 Financial Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on March 1 under the chairmanship of Alexandre Mérieux and approved the audited consolidated financial st...
-
17 Feb 2022
Business & Solutions
MYACUTECASE™, a free mobile application by bioMérieux to support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics
bioMérieux, a world leader in the field of in vitro diagnostics, launches MYACUTECASETM. This mobile application, the first of a kind developed by bioMérieux, is an aid in the interpretation of VIDAS®...